A Study to Assess the Relative Bioavailability of Risankizumab Following Subcutaneous Administrations With a Pre-Filled Syringe or an On-Body Injector in Healthy Adult Participants

Maximum Observed Plasma Concentration (Cmax) of Risankizumab

Maximum observed plasma concentration (Cmax) of Risankizumab

Time frame: Up to Approximately 113 days

Time to Cmax (Tmax) of Risankizumab

Tmax of Risankizumab

Time frame: Up to Approximately 113 days

Apparent Terminal Phase Elimination Rate Constant (β) of Risankizumab

Apparent terminal phase elimination rate constant (β) of Risankizumab

Time frame: Up to Approximately 113 days

Terminal Phase Elimination Half-life (t1/2) of Risankizumab

Terminal phase elimination half-life (t1/2) of Risankizumab

Time frame: Up to Approximately 113 days

Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Last Measurable Concentration (AUCt) of Risankizumab

AUCt of Risankizumab

Time frame: Up to Approximately 113 days

Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to Infinity (AUCinf) of Risankizumab

AUCinf of Risankizumab

Time frame: Up to Approximately 113 days

Number of Anti-drug antibodies (ADA)

Incidence of anti-drug antibodies

Time frame: Up to Approximately 113 days

Number of Participants Experiencing Adverse Events

An adverse event is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment